Iteos Therapeutics, Inc. Stock Price, News & Analysis

iTeos Therapeutics (ITOS) has announced upcoming poster presentations of preclinical data at the American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 25-30, 2025. The presentations will feature two key developments:

1. EOS-215: A potential best-in-class antibody targeting TREM2, designed to reprogram the tumor microenvironment and overcome resistance. This presentation is scheduled for April 28, 2025.

2. A novel PTPN1/2 inhibitor with high oral bioavailability that enhances antitumoral response, to be presented on April 29, 2025.

iTeos Therapeutics (ITOS) reported its Q4 and full year 2024 financial results, highlighting key developments in its immunotherapy pipeline. The company maintains a strong financial position with $655.0 million in cash, providing runway through 2027.

Key clinical milestones include anticipated topline interim data from GALAXIES Lung-201 in Q2 2025, featuring results from >240 patients, and interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC trials expected in 2025. The company completed enrollment for the second dose cohort of EOS-984 + pembrolizumab combination trial.

Financial results show R&D expenses increased to $145.4 million for 2024 (vs $113.3M in 2023), while G&A expenses decreased to $49.1 million (vs $50.4M in 2023). Net loss widened to $134.4 million ($3.32 per share) for 2024, compared to $112.6 million ($3.15 per share) in 2023.

iTeos Therapeutics (ITOS) has outlined its strategic priorities for 2025, highlighting multiple clinical data readouts for its TIGIT program. The company anticipates data from over 400 patients across three trials testing belrestotug + dostarlimab in lung and head & neck cancers. Key developments include Phase 2 data readouts in 2Q25 for NSCLC and throughout 2025 for HNSCC.

The company is advancing EOS-984, with Phase 1 data expected in 2H25, and plans to submit an IND for EOS-215, a potential best-in-class anti-TREM2 antibody, in 1Q25. iTeos maintains a strong financial position with $683.9 million in cash as of September 30, 2024, providing runway through 2027.

The GALAXIES Lung-301 Phase 3 trial has received FDA and NMPA clearance, while the Lung-201 study will report interim data including safety, ORR, and ctDNA data from over 240 patients in 2Q25.

iTeos Therapeutics (Nasdaq: ITOS), a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Michel Detheux, Ph.D., will deliver a presentation on Wednesday, January 15, 2025, at 7:30 AM PST (10:30 AM EST) in San Francisco.

Interested parties can access a live webcast of the presentation through the Investors section of iTeos's website at www.iteostherapeutics.com. The presentation recording will remain available for approximately 30 days after the event.

iTeos Therapeutics (ITOS) presented interim data from Phase 2 A2A-005 trial of inupadenant combined with carboplatin/pemetrexed in non-small cell lung cancer patients. The trial showed a 63.9% overall response rate and 7.7 months median progression-free survival across all cohorts. The recommended Phase 2 dose of 80mg demonstrated particularly strong results with a 73.3% response rate.

Despite encouraging initial signals, iTeos has decided to deprioritize inupadenant to focus resources on other programs, as the clinical activity did not meet sufficient levels for further investment. The safety profile was manageable with no dose-dependent toxicity observed.

iTeos Therapeutics (Nasdaq: ITOS) has announced its participation in two major investor conferences in December 2024. The company will attend the 7th Annual Evercore HealthCONx Conference on December 3 in Coral Gables, FL, featuring a fireside chat at 9:35 AM ET, and the Piper Sandler 36th Annual Healthcare Conference on December 4 in New York, NY, with a fireside chat scheduled for 11:30 AM ET.

Both events will include one-on-one investor meetings. The presentations will be available via live webcast on iTeos' website, with recordings accessible for approximately 30 days afterward.

iTeos Therapeutics (ITOS) reported Q3 2024 financial results and business updates. The company received EMA clearance for belrestotug 400mg + dostarlimab as Phase 3 dose for GALAXIES Lung-301 clinical sites in EU. Pro forma cash position stood at $683.9M as of September 30, 2024, expected to provide runway through 2027. Q3 R&D expenses increased to $36.7M from $30.6M year-over-year, while G&A expenses decreased to $12.1M from $12.6M. Net loss widened to $45.4M ($1.05 per share) compared to $32.2M ($0.90 per share) in Q3 2023.

iTeos Therapeutics (ITOS) announced upcoming presentations of preclinical, translational, and clinical data for inupadenant at the ESMO Immuno-Oncology Congress 2024 in Geneva. The presentations will include results from the Phase 2 A2A-005 trial studying inupadenant combined with platinum-doublet chemotherapy in post-immunotherapy metastatic non-small cell lung cancer (NSCLC) patients. The data will be presented through two mini oral presentations and one poster session on December 12, 2024, focusing on inupadenant's effects on humoral responses and its combination with chemotherapy in NSCLC patients.

iTeos Therapeutics announced promising interim data from the GALAXIES Lung-201 Phase 2 study, evaluating belrestotug + dostarlimab in first-line, PD-L1 high non-small cell lung cancer (NSCLC) patients. Key findings include:

1. Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed across all doses
2. Confirmed ORR (cORR) of ~60% for every dose, showing a >30% difference compared to dostarlimab monotherapy
3. Safety profile consistent with known checkpoint inhibitor combinations

The company believes these results support the potential differentiation of their TIGIT:PD-1 doublet and the ongoing GALAXIES Lung-301 Phase 3 registration study.